Abstract
Secretome of multipotent mesenchymal stromal cells (MSCs) is actively used in biomedical applications such as alveolar bone regeneration, treatment of cardiovascular disease, and neurodegenerative disorders. Nevertheless, hMSCs have low proliferative potential and production of the industrial quantity of their secretome might be challenging. Human fetal multipotent mesenchymal stromal cells (FetMSCs) isolated from early human embryo bone marrow are easy to expand and might be a potential source for pharmaceutical substances production based on their secretome. However, the secretome of FetMSCs was not previously analyzed. Here, we describe the secretome of FetMSCs using LC-MALDI shotgun proteomics. We identified 236 proteins. Functional annotation of the identified proteins revealed their involvement in angiogenesis, ossification, regulation of apoptosis, and immune response processes, which made it promising for biomedical applications. The proteins identified in the FetMSCs secretome are involved in the same biological processes as proteins from previously described adult hMSCs secretomes. Nevertheless, many of the common hMSCs secretome components (such as VEGF, FGF, Wnt and TGF-β) have not been identified in the FetMSCs secretome.
Highlights
Many human diseases come from the limits of tissue regenerative potential
While secretomes of hMSCs secretomes hMSCs from adult tissues have been at described in details at proteomics, from adult of tissues have been described in details proteomics, transcriptomics andtranscriptomics metabolomics and metabolomics levels, the secretome of fetal multipotent mesenchymal stromal cells (FetMSCs) been we describe the levels, the secretome of FetMSCs has not been studiedhas yet.not
FetMSCs line was originally isolated from bone marrow of early human embryo and described as multipotent mesenchymal stromal cells based on the Minimal criteria of The
Summary
Many human diseases come from the limits of tissue regenerative potential. Regenerative medicine focuses on the expansion of regenerative potential through control of tissue regeneration and cell proliferation/differentiation [1,2]. One of the promising approaches is the pluripotent embryonic stem cells (ESCs) treatment. ESCs have compromised genomic stability, which creates an obstacle to their use in therapy and increases the risk of carcinogenesis and immunologic rejection [4,5]. Multipotent mesenchymal stromal cells, on the other hand, have higher genomic stability, low carcinogenesis risk, and restricted proliferative potential, but might be differentiated into many cell types: bone, cartilage, adipose, skin, trachea, cornea, muscle, nerve, liver and myocardium [5,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
